BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: O'Connor A, Gisbert JP, O'Morain C, Ladas S. Treatment of Helicobacter pylori Infection 2015. Helicobacter. 2015;20 Suppl 1:54-61. [PMID: 26372826 DOI: 10.1111/hel.12258] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Arslan N, Yılmaz Ö, Demiray-Gürbüz E. Importance of antimicrobial susceptibility testing for the management of eradication in Helicobacter pylori infection. World J Gastroenterol 2017; 23(16): 2854-2869 [PMID: 28522904 DOI: 10.3748/wjg.v23.i16.2854] [Cited by in CrossRef: 37] [Cited by in F6Publishing: 34] [Article Influence: 7.4] [Reference Citation Analysis]
2 Harsha C, Banik K, Bordoloi D, Kunnumakkara AB. Antiulcer properties of fruits and vegetables: A mechanism based perspective. Food Chem Toxicol 2017;108:104-19. [PMID: 28711545 DOI: 10.1016/j.fct.2017.07.023] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
3 Sabbagh P, Mohammadnia-afrouzi M, Javanian M, Babazadeh A, Koppolu V, Vasigala VR, Nouri HR, Ebrahimpour S. Diagnostic methods for Helicobacter pylori infection: ideals, options, and limitations. Eur J Clin Microbiol Infect Dis 2019;38:55-66. [DOI: 10.1007/s10096-018-3414-4] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
4 Katelaris PH, Katelaris AL. A prospective evaluation of levofloxacin-based triple therapy for refractory Helicobacter pylori infection in Australia: Levofloxacin triple therapy for refractory H. pylori. Intern Med J 2017;47:761-6. [DOI: 10.1111/imj.13432] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
5 O'Connor A, O'Morain CA, Ford AC. Population screening and treatment of Helicobacter pylori infection. Nat Rev Gastroenterol Hepatol. 2017;14:230-240. [PMID: 28053340 DOI: 10.1038/nrgastro.2016.195] [Cited by in Crossref: 77] [Cited by in F6Publishing: 73] [Article Influence: 15.4] [Reference Citation Analysis]
6 Henriques PC, Costa LM, Seabra CL, Antunes B, Silva-Carvalho R, Junqueira-Neto S, Maia AF, Oliveira P, Magalhães A, Reis CA, Gartner F, Touati E, Gomes J, Costa P, Martins MCL, Gonçalves IC. Orally administrated chitosan microspheres bind Helicobacter pylori and decrease gastric infection in mice. Acta Biomater 2020;114:206-20. [PMID: 32622054 DOI: 10.1016/j.actbio.2020.06.035] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
7 Howden CW, Sheldon KL, Almenoff JS, Chey WD. Pitfalls of Physician-Directed Treatment of Helicobacter pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data. Dig Dis Sci 2021. [PMID: 34862940 DOI: 10.1007/s10620-021-07323-5] [Reference Citation Analysis]
8 Wu SC, Chen WT, Muo CH, Hsu CY. A Population-Based Cohort Study Examining the Long-term Risk of Repeated Surgery in Non-Helicobacter pylori-Infected PPU Patients Who Underwent Simple Closure. J Gastrointest Surg 2020;24:2587-95. [PMID: 31745904 DOI: 10.1007/s11605-019-04442-3] [Reference Citation Analysis]
9 Luo Y, You S, Wang J, Fan S, Shi J, Peng A, Yu T. Association between Sumoylation-Related Gene rs77447679 Polymorphism and Risk of Gastric Cancer (GC) in a Chinese Population. J Cancer 2017;8:3226-31. [PMID: 29158794 DOI: 10.7150/jca.20587] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
10 Ye ZM, Hu QY, Zheng JH, Zhang C, Zhu XD, Tang YM. A comprehensive evaluation of single nucleotide polymorphisms associated with gastric cancer risk: A protocol for systematic review and network meta-analysis. Medicine (Baltimore) 2020;99:e20448. [PMID: 32569167 DOI: 10.1097/MD.0000000000020448] [Reference Citation Analysis]
11 Keogan DM, Fagan LE, Passos TM, Müller-bunz H, Quilty B, Griffith DM. Synthesis of polymeric bismuth chlorido hydroxamato complexes; X-ray crystal structure and antibacterial activity of a novel Bi(III) salicylhydroxamato complex. Inorganica Chimica Acta 2017;460:134-40. [DOI: 10.1016/j.ica.2016.09.021] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
12 Camorlinga-Ponce M, Gómez-Delgado A, Aguilar-Zamora E, Torres RC, Giono-Cerezo S, Escobar-Ogaz A, Torres J. Phenotypic and Genotypic Antibiotic Resistance Patterns in Helicobacter pylori Strains From Ethnically Diverse Population in México. Front Cell Infect Microbiol 2020;10:539115. [PMID: 33643927 DOI: 10.3389/fcimb.2020.539115] [Reference Citation Analysis]
13 Kalfus IN, Graham DY, Riff DS, Panas RM. Rifabutin-Containing Triple Therapy (RHB-105) for Eradication of Helicobacter pylori: Randomized ERADICATE Hp Trial. Antibiotics (Basel) 2020;9:E685. [PMID: 33050205 DOI: 10.3390/antibiotics9100685] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
14 Sampaio PS, Calado CRC. Potential of FTIR-Spectroscopy for Drugs Screening against Helicobacter pylori. Antibiotics (Basel) 2020;9:E897. [PMID: 33322665 DOI: 10.3390/antibiotics9120897] [Reference Citation Analysis]
15 Song C, Qian X, Zhu Y, Shu X, Song Y, Xiong Z, Ye J, Yu T, Ding L, Wang H, Lu N, Xie Y. Effectiveness and safety of furazolidone‐containing quadruple regimens in patients with Helicobacter pylori infection in real‐world practice. Helicobacter 2019. [DOI: 10.1111/hel.12591] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
16 Fang CW, Chen CH, Muo CH, Wu SC. Risk of subsequent prostate cancer in peptic ulcer patients who received helicobacter pylori eradication therapy: an Asian population-based cohort study. BMC Urol 2020;20:135. [PMID: 32867754 DOI: 10.1186/s12894-020-00706-2] [Reference Citation Analysis]
17 Chua CS, Yang KC, Chen JH, Liu YH, Hsu YH, Lee HC, Huang SY. The efficacy of blueberry and grape seed extract combination on triple therapy for Helicobacter pylori eradication: a randomised controlled trial. Int J Food Sci Nutr 2016;67:177-83. [PMID: 26883189 DOI: 10.3109/09637486.2016.1144716] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
18 Panpetch W, Spinler JK, Versalovic J, Tumwasorn S. Characterization of Lactobacillus salivarius strains B37 and B60 capable of inhibiting IL-8 production in Helicobacter pylori-stimulated gastric epithelial cells. BMC Microbiol 2016;16:242. [PMID: 27756217 DOI: 10.1186/s12866-016-0861-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
19 周林, 赵阳鹏, 张伟. 幽门螺杆菌根除治疗在胃癌预防中的现状及前景. 世界华人消化杂志 2017; 25(15): 1327-1337 [DOI: 10.11569/wcjd.v25.i15.1327] [Reference Citation Analysis]
20 Darvishi M, Sadeghi S. Evaluation of Association of Helicobacter Pylori Infection and Coronary Heart Disease (CHD) among CCU Patients. J PURE APPL MICROBIO 2016;10:2621-6. [DOI: 10.22207/jpam.10.4.18] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
21 Semrau A, Gerold S, Frick JS, Iglauer F. Non-invasive detection and successful treatment of a Helicobacter pylori infection in a captive rhesus macaque. Lab Anim 2017;51:208-11. [PMID: 27609810 DOI: 10.1177/0023677216669179] [Reference Citation Analysis]
22 Ferenc S, Gnus J, Kościelna M, Kinda M, Yarka A, Stewart L, Witkiewicz W. High antibiotic resistance of Helicobacter pylori and its effect on tailored and empiric eradication of the organism in Lower Silesia, Poland. Helicobacter 2017;22. [PMID: 27879042 DOI: 10.1111/hel.12365] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
23 Fang C, Tseng C, Wu S, Chen WT, Muo C. Association of Vagotomy and Decreased Risk of Subsequent Ischemic Stroke in Complicated Peptic Ulcer Patients: an Asian Population Study. World J Surg 2017;41:3171-9. [DOI: 10.1007/s00268-017-4127-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
24 Ierardi E, Giorgio F, Iannone A, Losurdo G, Principi M, Barone M, Pisani A, Di Leo A. Noninvasive molecular analysis of Helicobacter pylori: Is it time for tailored first-line therapy? World J Gastroenterol 2017; 23(14): 2453-2458 [PMID: 28465629 DOI: 10.3748/wjg.v23.i14.2453] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 21] [Article Influence: 4.4] [Reference Citation Analysis]
25 Talebi Bezmin Abadi A. Helicobacter pylori treatment: New perspectives using current experience. Journal of Global Antimicrobial Resistance 2017;8:123-30. [DOI: 10.1016/j.jgar.2016.11.008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
26 Di Stefano M, Pagani E, Pesatori EV, Bergonzi M, Figura N, Corazza GR, Di Sabatino A. Polysorbate 80 add-on therapy in the treatment of Helicobacter pylori infection: Polysorbate 80 and HP antibiotic resistance. Clin Nutr ESPEN 2019;34:101-3. [PMID: 31677698 DOI: 10.1016/j.clnesp.2019.08.005] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]